Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

Journal Article (Journal Article)

Risk factors for acute GVHD (AGVHD), overall survival, and transplant-related mortality were evaluated in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from HLA-identical sibling donors (SDs; n = 3191) or unrelated donors (URDs; n = 2370) and reported to the Center for International Blood and Marrow Transplant Research, Minneapolis, MN. To understand the impact of transplant regimen on AGVHD risk, 6 treatment categories were evaluated: (1) myeloablative conditioning (MA) with total body irradiation (TBI) + PBSCs, (2) MA + TBI + BM, (3) MA + nonTBI + PBSCs, (4) MA + nonTBI + BM, (5) reduced intensity conditioning (RIC) + PBSCs, and (6) RIC + BM. The cumulative incidences of grades B-D AGVHD were 39% (95% confidence interval [CI], 37%-41%) in the SD cohort and 59% (95% CI, 57%-61%) in the URD cohort. Patients receiving SD transplants with MA + nonTBI + BM and RIC + PBSCs had significantly lower risks of grades B-D AGVHD than patients in other treatment categories. Those receiving URD transplants with MA + TBI + BM, MA + nonTBI + BM, RIC + BM, or RIC + PBSCs had lower risks of grades B-D AGVHD than those in other treatment categories. The 5-year probabilities of survival were 46% (95% CI, 44%-49%) with SD transplants and 33% (95% CI, 31%-35%) with URD transplants. Conditioning intensity, TBI and graft source have a combined effect on risk of AGVHD that must be considered in deciding on a treatment strategy for individual patients.

Full Text

Duke Authors

Cited Authors

  • Jagasia, M; Arora, M; Flowers, MED; Chao, NJ; McCarthy, PL; Cutler, CS; Urbano-Ispizua, A; Pavletic, SZ; Haagenson, MD; Zhang, M-J; Antin, JH; Bolwell, BJ; Bredeson, C; Cahn, J-Y; Cairo, M; Gale, RP; Gupta, V; Lee, SJ; Litzow, M; Weisdorf, DJ; Horowitz, MM; Hahn, T

Published Date

  • January 5, 2012

Published In

Volume / Issue

  • 119 / 1

Start / End Page

  • 296 - 307

PubMed ID

  • 22010102

Pubmed Central ID

  • PMC3251233

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

Digital Object Identifier (DOI)

  • 10.1182/blood-2011-06-364265


  • eng

Conference Location

  • United States